by The global corticosteroid eyedrops market size was valued at USD 19.89 billion in 2025 and is projected to increase to USD 21.08 billion in 2026. The market is further expected to reach USD 35.62 billion by 2035, expanding at a compound annual growth rate (CAGR) of 6.00% from 2026 to 2035. Market growth is primarily driven by the rising incidence of allergic conjunctivitis, increasing ophthalmic surgeries, and the rapid expansion of ophthalmologic clinics across emerging regions such as the Asia Pacific and Latin America.
Read Also: Cryoballoon Ablation System Market
Key Takeaways
-
North America dominated the market in 2025 with a 40% share.
-
Asia Pacific is projected to grow at the fastest CAGR of 6.5% through 2035.
-
By product type, Dexamethasone accounted for 35% of the market share in 2025.
-
Tobradex is expected to grow at a CAGR of 5.1% during the forecast period.
-
By application, adults held 80% of the market share in 2025.
-
The children segment is projected to expand at a CAGR of 5.3%.
-
Hospital pharmacies led distribution with a 45% market share in 2025.
-
Online pharmacies are forecasted to grow at a CAGR of 5.7%.
Market Overview
The corticosteroid eyedrops market includes ophthalmic steroid formulations used to treat:
-
Ocular inflammation
-
Post-surgical swelling
-
Uveitis
-
Allergic conjunctivitis
-
Other inflammatory eye disorders
These medications reduce inflammation by suppressing immune responses in eye tissues. Growing geriatric populations, increasing surgical interventions such as cataract and LASIK, and improved access to healthcare services are fueling demand globally.
How Artificial Intelligence is Transforming the Market
Artificial Intelligence (AI) is playing a transformative role in the corticosteroid eyedrops industry by shifting it toward precision-based, data-driven drug development.
AI enables:
-
Optimization of drug solubility and stability
-
Improved formulation design
-
Reduced side effects
-
Enhanced therapeutic adherence
-
Faster drug discovery timelines
Latest Market Trends
1. Expansion of Production Facilities
Leading manufacturers are expanding production capacities to meet rising demand.
In October 2025, Aurolab opened a new production center in Madurai, India, capable of producing approximately 36 million bottles of eyedrops annually.
2. Rising Prevalence of Eye Disorders
According to the American Academy of Ophthalmology, approximately 7.32 million Americans are projected to suffer from primary open-angle glaucoma by 2050, significantly increasing demand for corticosteroid-based treatments.
3. Regulatory Approvals Boosting Market Growth
In December 2024, the U.S. Food and Drug Administration approved Omnipred, an adrenocortical steroid-based eyedrop effective in treating acne rosacea and superficial punctate keratitis.
4. Growing Adoption of Advanced Formulations
-
Preservative-free corticosteroid eyedrops
-
Sustained-release formulations
-
Nano-technology-based suspensions
These innovations improve tolerability and patient compliance while minimizing adverse effects.
5. Increasing Popularity of Combination Therapies
Combination products, such as corticosteroid plus antibiotic formulations, are gaining traction due to their ability to treat inflammation and infections simultaneously.
Segment Insights
Product Type Insights
Why Did Dexamethasone Dominate?
The dexamethasone segment held the largest share of 35% in 2025 due to:
-
High anti-inflammatory efficacy
-
Broad application in uveitis and postoperative inflammation
-
Compatibility with antibiotic combinations
Major manufacturers include:
-
Amneal Pharmaceuticals
-
ANI Pharmaceuticals
-
Allergan
Tobradex Growth Outlook
Tobradex is projected to grow at a CAGR of 5.1% due to its dual-action formula combining corticosteroid and tobramycin antibiotic, widely used in refractive surgery aftercare.
Application Insights
Adults Segment Dominance
The adult segment accounted for 80% of the market share in 2025 due to:
-
Increasing cataract and LASIK procedures
-
Higher incidence of dry eye syndrome
-
Growing cases of uveitis and age-related macular degeneration
According to the College of Optometrists, late-stage macular degeneration in the UK is expected to increase by 24.4% by 2035 compared to 2025.
Children Segment Growth
The pediatric segment is projected to grow at a CAGR of 5.3%, supported by:
-
Rising cases of vernal keratoconjunctivitis (VKC)
-
Increased caregiver awareness
-
Expansion of pediatric eye care services
Distribution Channel Insights
Why Hospital Pharmacies Led in 2025
Hospital pharmacies held a 45% share due to:
-
High volume of ophthalmic surgeries
-
Strong prescription-based purchasing
-
Better reimbursement systems
Online Pharmacies: Fastest Growing
Online pharmacies are forecasted to grow at 5.7% CAGR due to:
-
Competitive pricing
-
Smartphone-driven convenience
-
Subscription models and reminders
In August 2025, Zepto launched Zepto Pharmacy, offering rapid medicine delivery services in India.
Regional Insights
North America Market Analysis
The North American market was valued at USD 7.96 billion in 2025 and is projected to reach USD 14.43 billion by 2035, growing at a CAGR of 6.13%.
Why North America Dominates
-
Advanced healthcare infrastructure
-
High surgical volumes
-
Strong presence of leading players such as Alcon and Harrow
-
Supportive reimbursement policies
In January 2026, Maryland Vision Institute partnered with Busack Eye Center to expand ophthalmologic services in Maryland.
U.S. Market Outlook
The U.S. corticosteroid eyedrops market was valued at USD 5.97 billion in 2025 and is projected to reach USD 10.89 billion by 2035, growing at a CAGR of 6.20%.
Growth drivers include:
-
Nano-technology-based formulations
-
Rising diabetic retinopathy and glaucoma cases
-
Increased production capacity expansions
Asia Pacific – Fastest Growing Region
Asia Pacific is expected to grow at the fastest CAGR of 6.5% due to:
-
Rising awareness of eye health
-
Expanding geriatric population
-
Increasing medical tourism
-
Demand for affordable generics
In December 2025, Santen Pharmaceutical launched Verkazia in China for treating severe VKC in children and young adults.
China leads the regional market due to strong online pharmacy adoption and growing pharmaceutical investments.
Competitive Landscape
Key players operating in the corticosteroid eyedrops market include:
-
Pfizer Inc.
-
AbbVie Inc.
-
Novartis AG
-
Bausch Health Companies Inc.
-
Sun Pharmaceutical Industries Ltd.
-
Cipla Ltd.
-
Lupin Limited
-
Zydus Lifesciences Ltd.
For inquiries regarding discounts, bulk purchases, or customization requests, please contact us at sales@precedenceresearch.com
